Please Wait
Applying Filters...
menu
    • menu
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Naldemedine Tosylate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 86,335Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Symproic, Naldemedine tosilate, Naldemedine tosylate [usan], Naldemedine (tosylate), V1n8f1rvvo, 1345728-04-2
    Molecular Formula
    C39H42N4O9S
    Molecular Weight
    742.8  g/mol
    InChI Key
    WCYDLROFMZJJLE-RTMHEQJQSA-N
    FDA UNII
    V1N8F1RVVO
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,7,9-trihydroxy-N-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl]-1,2,4,5,7a,13-hexahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-6-carboxamide;4-methylbenzenesulfonic acid
    2.1.2 InChI
    InChI=1S/C32H34N4O6.C7H8O3S/c1-30(2,29-33-27(35-42-29)18-6-4-3-5-7-18)34-28(39)20-15-32(40)22-14-19-10-11-21(37)25-23(19)31(32,26(41-25)24(20)38)12-13-36(22)16-17-8-9-17;1-6-2-4-7(5-3-6)11(8,9)10/h3-7,10-11,17,22,26,37-38,40H,8-9,12-16H2,1-2H3,(H,34,39);2-5H,1H3,(H,8,9,10)/t22-,26+,31+,32-;/m1./s1
    2.1.3 InChI Key
    WCYDLROFMZJJLE-RTMHEQJQSA-N
    2.1.4 Canonical SMILES
    CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C(C4C56CCN(C(C5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
    2.1.5 Isomeric SMILES
    CC1=CC=C(C=C1)S(=O)(=O)O.CC(C)(C1=NC(=NO1)C2=CC=CC=C2)NC(=O)C3=C([C@H]4[C@@]56CCN([C@@H]([C@@]5(C3)O)CC7=C6C(=C(C=C7)O)O4)CC8CC8)O
    2.2 Other Identifiers
    2.2.1 UNII
    V1N8F1RVVO
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 17-(cyclopropylmethyl)-6,7-didehydro-4,5alpha-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl- 1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide

    2. Naldemedine

    3. S-297995

    4. Symproic

    2.3.2 Depositor-Supplied Synonyms

    1. Symproic

    2. Naldemedine Tosilate

    3. Naldemedine Tosylate [usan]

    4. Naldemedine (tosylate)

    5. V1n8f1rvvo

    6. 1345728-04-2

    7. Unii-v1n8f1rvvo

    8. Symproic (tn)

    9. Chembl3039508

    10. Schembl20720003

    11. Dtxsid10158809

    12. Naldemedine Tosylate [mi]

    13. Naldemedine Tosylate (jan/usan)

    14. Naldemedine Tosilate [jan]

    15. Hy-19627a

    16. Naldemedine Tosilate [who-dd]

    17. Naldemedine Tosylate [orange Book]

    18. Cs-0030916

    19. D10478

    20. Q27291424

    21. 17-(cyclopropylmethyl)-6,7-didehydro-4,5a-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide 4-methylbenzenesulfonic Acid

    22. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5.alpha.)-, 4-methylbenzenesulfonate (1:1)

    23. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-, 4-methylbenzenesulfonate (1:1)

    2.4 Create Date
    2012-03-19
    3 Chemical and Physical Properties
    Molecular Weight 742.8 g/mol
    Molecular Formula C39H42N4O9S
    Hydrogen Bond Donor Count5
    Hydrogen Bond Acceptor Count12
    Rotatable Bond Count7
    Exact Mass742.26725010 g/mol
    Monoisotopic Mass742.26725010 g/mol
    Topological Polar Surface Area204 Ų
    Heavy Atom Count53
    Formal Charge0
    Complexity1340
    Isotope Atom Count0
    Defined Atom Stereocenter Count4
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count2
    4 Drug and Medication Information
    4.1 Drug Information
    1 of 1  
    Drug NameSYMPROIC
    Active IngredientNALDEMEDINE TOSYLATE
    CompanySHIONOGI INC (Application Number: N208854. Patents: 9108975, RE46365, RE46375)

    4.2 Drug Indication

    Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.

    Treatment of opioid-induced constipation (OIC)

    5 Pharmacology and Biochemistry
    5.1 ATC Code

    A06AH05